source
- Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugsViatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…
- FDA extends safety review of mifepristone into next year, report due by March 2027The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year. The agency expects to finish the saf…